Norway Glp-1 Agonists Weight Loss Drugs Market Size & Outlook

Name: Norway Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The glp-1 agonists weight loss drugs market in Norway is expected to reach a projected revenue of US$ 376.9 million by 2033. A compound annual growth rate of 10.63% is expected of Norway glp-1 agonists weight loss drugs market from 2026 to 2033.

Norway glp-1 agonists weight loss drugs drug outlook (Revenue, USD million, 2021-2033)
- Semaglutide (Wegovy)
- Liraglutide (Saxenda)
- Tirzepatide (Zepbound)
- Other Drugs
Norway glp-1 agonists weight loss drugs route of administration outlook (Revenue, USD million, 2021-2033)
- Parenteral
- Oral
Norway glp-1 agonists weight loss drugs distribution channel outlook (Revenue, USD million, 2021-2033)
- Retail Pharmacies
- Hospital Pharmacies
- Other Pharmacies

Norway Glp-1 Agonists Weight Loss Drugs Market Size & Outlook

Sign up - it's easy, and free!